Scancell raises £8.7 million in share placement

The UK cancer vaccine company Scancell Holdings Plc has raised £8.7 million from existing and new shareholders in order to advance its portfolio of early clinical stage vaccines for melanoma, non-small cell lung cancer and other solid tumours.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom